Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Summit Therapeutics (SMMT) over the last 10 years, with Q3 2025 value amounting to -$71000.0.

  • Summit Therapeutics' Cash from Investing Activities rose 9993.46% to -$71000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $394.3 million, marking a year-over-year increase of 27275.81%. This contributed to the annual value of -$205.3 million for FY2024, which is 6506.46% up from last year.
  • Summit Therapeutics' Cash from Investing Activities amounted to -$71000.0 in Q3 2025, which was up 9993.46% from $150.8 million recorded in Q2 2025.
  • In the past 5 years, Summit Therapeutics' Cash from Investing Activities registered a high of $160.1 million during Q1 2025, and its lowest value of -$645.1 million during Q1 2023.
  • For the 5-year period, Summit Therapeutics' Cash from Investing Activities averaged around -$25.4 million, with its median value being -$39000.0 (2021).
  • Data for Summit Therapeutics' Cash from Investing Activities shows a peak YoY increase of 60558000.0% (in 2023) and a maximum YoY decrease of 17858781.16% (in 2023) over the last 5 years.
  • Over the past 5 years, Summit Therapeutics' Cash from Investing Activities (Quarter) stood at -$120000.0 in 2021, then surged by 108.33% to $10000.0 in 2022, then skyrocketed by 605580.0% to $60.6 million in 2023, then surged by 37.83% to $83.5 million in 2024, then plummeted by 100.09% to -$71000.0 in 2025.
  • Its last three reported values are -$71000.0 in Q3 2025, $150.8 million for Q2 2025, and $160.1 million during Q1 2025.